Try a new search

Format these results:

Searched for:

person:griesa02

in-biosketch:true

Total Results:

110


Center use of technical variant grafts varies widely and impacts pediatric liver transplant waitlist and recipient outcomes in the United States

Mazariegos, George V; Perito, Emily R; Squires, James E; Soltys, Kyle A; Griesemer, Adam D; Taylor, Sarah A; Pahl, Eric
To assess the impact of technical variant grafts (TVG) (including living donor [LD] and deceased donor split/partial grafts) on waitlist (WL) and transplant outcomes for pediatric liver transplant (LT) candidates, we performed a retrospective analysis of OPTN data on first-time LT or liver-kidney pediatric candidates listed at centers that performed >10 LT during the study period, 2004-2020. Center variance was plotted for LT volume, TVG usage, and survival. A composite center metric of TVG usage and WL mortality was developed to demonstrate existing variation and potential for improvement. 64 centers performed 7842 LT; 657 children died on the WL. Proportions of WL mortality by center ranged from 0-31% and TVG usage from 0-76%. Higher TVG usage, from deceased or LD, independently or in combination, significantly correlated with lower WL mortality. In multivariable analyses, death from listing was significantly lower with increased center TVG usage (HR 0.611, CI [0.40-0.92]) and LT volume (HR 0.995, CI [0.99-1.0]). Recipients of living donor transplants (HR 0.637, CI [0.51-0.79]) had significantly increased survival from transplant compared with other graft types, and recipients of deceased donor technical variant grafts (HR 1.066, CI [0.93-1.22]) had statistically similar outcomes compared to whole graft recipients. Increased TVG utilization may decrease WL mortality in the U.S. Policy and training to increase TVG usage, availability and expertise is critical.
PMID: 36746117
ISSN: 1527-6473
CID: 5420752

Next steps for the xenotransplantation of pig organs into humans

Montgomery, Robert A; Mehta, Sapna A; Parent, Brendan; Griesemer, Adam
PMID: 35941375
ISSN: 1546-170x
CID: 5286742

Results of Two Cases of Pig-to-Human Kidney Xenotransplantation [Case Report]

Montgomery, Robert A; Stern, Jeffrey M; Lonze, Bonnie E; Tatapudi, Vasishta S; Mangiola, Massimo; Wu, Ming; Weldon, Elaina; Lawson, Nikki; Deterville, Cecilia; Dieter, Rebecca A; Sullivan, Brigitte; Boulton, Gabriella; Parent, Brendan; Piper, Greta; Sommer, Philip; Cawthon, Samantha; Duggan, Erin; Ayares, David; Dandro, Amy; Fazio-Kroll, Ana; Kokkinaki, Maria; Burdorf, Lars; Lorber, Marc; Boeke, Jef D; Pass, Harvey; Keating, Brendan; Griesemer, Adam; Ali, Nicole M; Mehta, Sapna A; Stewart, Zoe A
BACKGROUND:Xenografts from genetically modified pigs have become one of the most promising solutions to the dearth of human organs available for transplantation. The challenge in this model has been hyperacute rejection. To avoid this, pigs have been bred with a knockout of the alpha-1,3-galactosyltransferase gene and with subcapsular autologous thymic tissue. METHODS:We transplanted kidneys from these genetically modified pigs into two brain-dead human recipients whose circulatory and respiratory activity was maintained on ventilators for the duration of the study. We performed serial biopsies and monitored the urine output and kinetic estimated glomerular filtration rate (eGFR) to assess renal function and xenograft rejection. RESULTS:in Recipient 2. In both recipients, the creatinine level, which had been at a steady state, decreased after implantation of the xenograft, from 1.97 to 0.82 mg per deciliter in Recipient 1 and from 1.10 to 0.57 mg per deciliter in Recipient 2. The transplanted kidneys remained pink and well-perfused, continuing to make urine throughout the study. Biopsies that were performed at 6, 24, 48, and 54 hours revealed no signs of hyperacute or antibody-mediated rejection. Hourly urine output with the xenograft was more than double the output with the native kidneys. CONCLUSIONS:Genetically modified kidney xenografts from pigs remained viable and functioning in brain-dead human recipients for 54 hours, without signs of hyperacute rejection. (Funded by Lung Biotechnology.).
PMID: 35584156
ISSN: 1533-4406
CID: 5230812

Autologous Stem Cell Transplant to Treat Recurrent Primary Sclerosing Cholangitis: Tolerance, but at What Price?

Griesemer, Adam; Martinez, Mercedes; Emond, Jean C
PMID: 34033607
ISSN: 1534-6080
CID: 5151332

Pediatric Living Donor Liver Transplantation: Optimizing Outcomes for Recipients, Donors, and the Waiting List [Editorial]

Duggan, Erin M; Griesemer, Adam D
PMID: 34822221
ISSN: 1527-6473
CID: 5151342

First Report of Xenotransplantation from a Pig to Human Recipient [Meeting Abstract]

Stern, J; Tatapudi, V; Lonze, B; Stewart, Z; Mangiola, M; Wu, M; Mehta, S; Weldon, E; Dieter, R; Lawson, N; Griesemer, A; Parent, B; Piper, G; Sommer, P; Cawthon, S; Sullivan, B; Ali, N; Montgomery, R
ORIGINAL:0015582
ISSN: 1600-6143
CID: 5231032

Factors associated with thrombotic and hemorrhagic complications in pediatric liver transplantation: A multi-center analysis from the Starzl Network for Excellence in Pediatric Transplantation [Meeting Abstract]

Soltys, Kyle; Zhang, Xingyu; Confair, C. J.; Superina, Riccardo; Lemoine, Caroline; Rasmussen, Sara; Bucuvalas, John; Griesemer, Adam; Sayed, Blayne; Romero, Rene; Batsis, Irini; Mazariegos, George
ISI:000739470700179
ISSN: 1600-6135
CID: 5161222

Cytokine Analysis of First Gal-KO Renal Xenotransplantation From a Pig-To-Human Recipient [Meeting Abstract]

Stern, Jeffrey; Lonze, Bonnie E.; Stewart, Zoe A.; Mangiola, Massimo; Tatapudi, Vasishta; Zhang, Weimin; Camellato, Brendan; Xia, Bo; Boeke, Jef; Pass, Harvey; Weldon, Elaina; Lawson, Nikki; Griesemer, Adam; Keating, Brendan; Montgomery, Robert A.
ISI:000889117001034
ISSN: 0041-1337
CID: 5479262

Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma [Case Report]

Kang, Elise; Martinez, Mercedes; Moisander-Joyce, Hanna; Saenger, Yvonne M; Griesemer, Adam D; Kato, Tomoaki; Yamashiro, Darrell J; Remotti, Helen; Gartrell, Robyn D
BACKGROUND:Immunotherapy, specifically immune checkpoint inhibitors (ICIs), including anti-programmed cell death 1 (anti-PD1), has recently received clinical approval for the treatment of adult hepatocellular carcinoma (HCC). However, the safety and efficacy of ICIs prior to solid organ transplant are unknown, especially in pediatrics. Safety reports are variable in adults, with some series describing subsequent allograft rejection and loss while others report successful transplants without allograft rejection.As ICIs stimulate the immune system by blocking the interaction between PD1 and the ligand-receptor pair programmed cell death-ligand 1 (PDL1), the downstream effects of T-cell activation increase the risk of graft rejection. METHODS:Here, we present a case of an adolescent with moderately differentiated non-fibrolamellar HCC treated with pembrolizumab, an anti-PD1 therapy, who subsequently underwent successful orthotopic liver transplantation (OLT). RESULTS:Our patient received an OLT 138 days from the last pembrolizumab dose with graft preservation. The patient has no evidence of recurrent disease or any episode of allograft rejection 48 months post OLT. Staining of tumor and normal tissues from longitudinal specimens finds PDL1 positive Kupffer cells present in normal liver and peritumoral areas with no changes post anti-PD1 therapy. In contrast, tumor cells were negative for PDL1. CONCLUSION/CONCLUSIONS:This case represents a basis for optimism in potential use of anti-PD1 therapy in liver transplant candidates and supports further investigation of immune checkpoint inhibitors use in this unique patient population.
PMID: 34907641
ISSN: 1399-3046
CID: 5151352

Risk Factors for 30-Day Unplanned Readmission After Hepatectomy: Analysis of 438 Pediatric Patients from the ACS-NSQIP-P Database

Kang, Elise; Shin, John Inho; Griesemer, Adam D; Lobritto, Steven; Goldner, Dana; Vittorio, Jennifer M; Stylianos, Steven; Martinez, Mercedes
BACKGROUND:Hepatic resections are uncommon in children. Most studies reporting complications of these procedures and risk factors associated with unplanned readmissions are limited to retrospective data from single centers. We investigated risk factors for 30-day unplanned readmission after hepatectomy in children using the American College of Surgeons National Surgical Quality Improvement-Pediatric database. METHODS:The database was queried for patients aged 0-18 years who underwent hepatectomy for the treatment of liver lesions from 2012 to 2018. Chi-squared tests were performed to evaluate for potential risk factors for unplanned readmissions. A multivariate regression analysis was performed to identify independent predictors for unplanned 30-day readmissions. RESULTS:Among 438 children undergoing hepatectomy, 64 (14.6%) had unplanned readmissions. The median age of the hepatectomy cohort was 1 year (0-17); 55.5% were male. Patients readmitted had significantly higher rates of esophageal/gastric/intestinal disease (26.56% vs. 14.97%; p=0.022), current cancer (85.94% vs. 75.67%; p=0.012), and enteral and parenteral nutritional support (31.25% vs. 17.65%; p=0.011). Readmitted patients had significantly higher rates of perioperative blood transfusion (67.19% vs. 52.41%; p=0.028), organ/space surgical site infection (10.94% vs. 1.07%; p<.001), sepsis (15.63% vs. 3.74%; p<.001), and total parenteral nutrition at discharge (9.09% vs. 2.66%; p=0.041). Organ/space surgical site infection was an independent risk factor for unplanned readmission (OR=9.598, CI [2.070-44.513], p=0.004) by multivariable analysis. CONCLUSION:Unplanned readmissions after liver resection are frequent in pediatric patients. Organ/space surgical site infections may identify patients at increased risk for unplanned readmission. Strategies to reduce these complications may decrease morbidity and costs associated with unplanned readmissions.
PMID: 33825121
ISSN: 1873-4626
CID: 5151322